The annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI), held Feb. 20-24 in Houston, brought together thousands of attendees for this annual event, which traditionally generates headlines with new scientific findings, many within the food allergy field.
The preliminary results of a double-blind, placebo-controlled Phase IIb “peanut patch” study led by Hugh A. Sampson, MD, director of the Jaffe Food Allergy Institute at the Kravis Children’s Hospital at Mount Sinai and chair of FARE’s Medical Advisory Board, suggest a new treatment option may be on the horizon for those with peanut allergy in the years to come. Sampson presented results of the peanut patch (known as Viaskin® Peanut) study as part of a late-breaking abstract.
Using epicutaneous immunotherapy, three different amounts of peanut protein (50, 100 or 250 micrograms) or a placebo were randomly provided to 113 children, 73 adolescents and teens, and 35 adults over the course of one year.
After one year of therapy, half of the patients treated with the 250-microgram patch could tolerate about four peanuts – 10 times the dose they tolerated in their initial oral peanut challenge, Sampson explained in a news release. No serious reactions were reported.
“The results of the peanut patch study are encouraging especially in terms of its safety, and we look forward to further evaluation,” said FARE CEO James R. Baker, Jr., MD.
It is important to note that the results discussed here are preliminary, and have not yet been fully published in peer-reviewed scientific journals. To read the abstract, visit the Journal of Allergy and Clinical Immunology.
As in years past, members of FARE’s leadership team attended the AAAAI event, where members of the FARE’s Research Advisory Board convened. FARE also hosted a reception for researchers, which provided an opportunity for those newer to the field to exchange ideas with each other and with veteran investigators.